Silo Pharma ( (SILO) ) has shared an update.
Silo Pharma, Inc. has released a presentation outlining its strategic direction and product pipeline, which includes innovative treatments for unmet medical needs such as PTSD, chronic pain, and CNS diseases. Emphasizing their approach to drug development, Silo Pharma is leveraging novel formulations and drug delivery systems, including psychedelics. They plan to utilize the FDA’s 505(b)(2) regulatory pathway for faster approval of their priority candidates. Investors should note the forward-looking nature of the statements and the inherent risks involved.
See more insights into SILO stock on TipRanks’ Stock Analysis page.
